No Increased Risk Of Treatment-Induced Augmentation In Restless Legs Syndrome Demonstrated In Long-Term Placebo-Controlled Study With Mirapexin/Sifrol

New data presented at the 61st Annual Meeting of the American Academy of Neurology (AAN), in Seattle, U.S.A. show that augmentation did not significantly differ in RLS patients treated with Mirapexin® /Sifrol® (pramipexole*) versus the group receiving placebo.1Augmentation, i.e. the worsening of RLS symptoms due to pharmacological treatment, has been frequently observed in patients treated with levodopa, a dopaminergic agent sometimes used to treat RLS.